The Neo-Bioscore appeared to be the superior system for evaluation of patients undergoing neoadjuvant therapy. This will likely lead to more consistent adoption of this clinical tool.— Kelly M. McMasters, MD, PhD
“More and more, we are finding that traditional anatomic TNM staging has significant limitations in predicting prognosis, especially in such cases where response to therapy is an important consideration,” commented session moderator Kelly M. McMasters, MD, PhD, a surgical oncologist at the University of Louisville School of Medicine, Kentucky.
“This was a well-conducted retrospective analysis to compare several different approaches in a large group of patients. They found that the Neo-Bioscore, developed at MD Anderson Cancer Center, appeared to be the superior system for evaluation of patients undergoing neoadjuvant therapy,” he said. “This will likely lead to more consistent adoption of this clinical tool. Of course, like all models, it can be improved with further research in the future.” ■
Disclosure: Dr. McMasters reported no potential conflicts of interest.
John R. Bergquist, MD, MS, MA, received the third annual Susan G. Komen Breast Cancer Research Award. This award is given to a postdoctoral breast fellow or newly trained surgical oncologist interested in breast cancer research who...